Navigation Links
Onyx Pharmaceuticals to Present at the Baird 2010 Growth Stock Conference
Date:5/11/2010

EMERYVILLE, Calif., May 11 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at Baird's 2010 Growth Stock Conference on Tuesday, May 18, 2010 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).  

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.  For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentations through June 1, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer.  The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types.  Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing.  For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... company announces that its technology partner Mannin Research Inc. ... and Ophthalmology (ARVO), which takes place from May 1-5, ... Research executives will be meeting with its vendors and ... further explore business development goals and other collaborative opportunities ...
(Date:5/2/2016)... ... , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of remote ... modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 ... PC over encrypted SSH. , Traditionally, users of PC X servers deploy the XDMCP ...
(Date:4/29/2016)... ... ... The MIT bioLogic design team has won multiple A' Design Awards ... be applied to fabric and formed into living interfaces between body and environment. They ... The team harvested Natto cells and applied them to fabric with custom 3D printers.The ...
(Date:4/29/2016)... GA (PRWEB) , ... April 29, 2016 , ... ... of medical devices used in spinal surgical procedures, today announced the completion of ... enhanced value proposition for current and future customers and partners. Kohlberg & ...
Breaking Biology Technology:
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
(Date:3/3/2016)... NOTTINGHAM, England and DE SOTO, ... , U.S.-based Stroke Detection Plus® to offer Oncimmune,s ... the risk assessment and early detection of lung cancer ... include large employers, unions and individuals. --> ... employers, unions and individuals. --> Oncimmune, a ...
(Date:3/2/2016)... DUBLIN , March 2, 2016 /PRNewswire/ ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics as a Service ... --> Research and Markets ...
Breaking Biology News(10 mins):